التفاصيل البيبلوغرافية
| العنوان: |
Dose-and time-dependent therapeutic benefit of SC31. |
| المؤلفون: |
Conrad E. Z. Chan (11014434), Shirley G. K. Seah (11014437), De Hoe Chye (11014440), Shane Massey (224366), Maricela Torres (11014443), Angeline P. C. Lim (11014446), Steven K. K. Wong (11014449), Jacklyn J. Y. Neo (11014452), Pui San Wong (11014455), Jie Hui Lim (11014458), Gary S. L. Loh (11014461), Dongling Wang (258597), Jerome D. Boyd-Kirkup (11014464), Siyu Guan (11014467), Dipti Thakkar (11014470), Guo Hui Teo (1521718), Kiren Purushotorman (11014473), Paul E. Hutchinson (6458183), Barnaby E. Young (10869381), Jenny G. Low (10499731), Paul A. MacAry (10534724), Hannes Hentze (6680750), Venkateshan S. Prativadibhayankara (11014476), Kantharaj Ethirajulu (2100358), Jason E. Comer (7908407), Chien-Te K. Tseng (492742), Alan D. T. Barrett (8980565), Piers J. Ingram (11014479), Trevor Brasel (502095), Brendon John Hanson (11014482) |
| سنة النشر: |
2021 |
| المجموعة: |
Smithsonian Institution: Digital Repository |
| مصطلحات موضوعية: |
Biochemistry, Microbiology, Cell Biology, Molecular Biology, Pharmacology, Biotechnology, Ecology, Immunology, Cancer, Infectious Diseases, Virology, convalescent COVID -19 patient, anti-SARS-CoV -2 activities, SARS-CoV -2-infected hamsters, IFN, K 18-human ACE 2, attenuated pro-inflammatory responses, SARS-CoV -2 Spike protein, efficacy, Fc-null LALA variant, COVID -19. Importantly, Fc-mediated effector functions, SARS-CoV -2 neutralizing antibody, SC 31 treatment, SARS-CoV -2-neutralizing antibodies, SC 31 |
| الوصف: |
Groups of 10 SARS-Cov-2 infected K18-hACE2 mice were treated with SC31 IgG1 or isotype control at the indicated doses 6 hpi. Half of the mice (n = 5) were sacrificed at 3 dpi to assess lung viral load; the remaining mice were monitored for weight changes and survival. Lung viral load as measured by ( A ) qRT-PCR and ( B ) cell culture, the limit of detection (LOD) is indicated by the dotted line. Disease progression is indicated by ( C ) weight loss and ( D) survival. For the time-dependent study, SC31 IgG1 was administered at 20 mg/kg at the indicated time points. Half of the mice (n = 5) were sacrificed at 3 dpi to assess lung viral load and cytokine levels in addition to serum antibody titers. Remaining mice were monitored for weight changes and survival. Lung viral load as measured by ( E ) qRT-PCR and ( F ) cell culture, the limit of detection (LOD) is indicated by the dotted line. Disease progression in infected mice as indicated by ( G ) weight loss and ( H ) survival. ( I ) Lung cytokine mRNA expression determined by qRT-PCR and represented as fold-change over uninfected mice. Each point represents one individual mouse and all error bars show standard error. Statistical significance was determined using two-way ANOVA with Fisher’s LSD test for viral load, D5-6 weight loss or cytokines/chemokines and Chi-Square for D15 survival percentage, ns–p>0.05, * p<0.05, **p<0.01, ***p<0.001 vs. untreated. |
| نوع الوثيقة: |
still image |
| اللغة: |
unknown |
| Relation: |
https://figshare.com/articles/figure/Dose-and_time-dependent_therapeutic_benefit_of_SC31_/14830491 |
| DOI: |
10.1371/journal.pone.0253487.g004 |
| الاتاحة: |
https://doi.org/10.1371/journal.pone.0253487.g004 |
| Rights: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.52607DEB |
| قاعدة البيانات: |
BASE |